Added to YB: 2026-03-11
Pitch date: 2026-03-09
CDIO [neutral]
Cardio Diagnostics Holdings, Inc.
-7.69%
current return
Author Info
Stock Pursuit researches domestic deep value equities below net cash, net current asset value or net tangible assets. Sign up for the newsletter.
Company Info
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.
Market Cap
$9.7M
Pitch Price
$4.94
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.64
P/E
-1.31
EV/Sales
241.38
Sector
Biotechnology
Category
growth
Cardio Diagnostics (CDIO) Updates
CDIO (update): CMS paying $854 for both tests (vs $350-$685 prelim). Partnered w/ Dr. Lal PathLabs (290 labs) in India for PrecisionCHD. New study validates detection ability vs exercise stress treadmill. 146M Americans eligible for Epi+ test, 60M for PrecisionCHD. Est $113M yr1 cost savings to insurers. Growing sales pipeline. Stock +300% past month, offering expected.
Read full article (2 min)